Log inSign Up
Nata Savaścienka CPO
January 23, 2026
Two weeks ago, we wrote about OpenAI's ChatGPT Health launch. Since then, the landscape shifted further: OpenAI followed with OpenAI for Healthcare (enterprise B2B), Anthropic announced Claude for Healthcare, and the FDA released revised Clinical Decision Support guidance that creates new opportunities for clinician-facing AI tools.
Healthcare AI is entering its enterprise era. For organizations handling blood test results, lab work interpretation, and biomarker analysis at scale, the path forward looks different than consumer AI headlines suggest.
On January 6, 2026, the FDA issued updated Clinical Decision Support Software guidance, superseding the 2022 version. FDA Commissioner Marty Makary framed it as intended to "cut unnecessary regulation and promote innovation."
Single recommendation outputs are no longer disqualifying. The 2022 guidance created anxiety because software providing a "specific preventive, diagnostic, or treatment output" risked medical device classification. The 2026 revision: FDA will exercise enforcement discretion when software presents one clinically appropriate recommendation, as long as it meets non-device CDS criteria and enables clinician review.
The catch? It must be a "Glass Box." You can give the single best answer, but you must show your work. The clinician must click through and see the logic, data, or guidelines that led to the recommendation. For LLM-based systems, outputs must be grounded in verifiable sources. Hallucinated citations are not acceptable.
Risk scoring gets nuanced treatment. Risk predictions no longer automatically push software toward device classification when grounded in accepted evidence and reviewable by clinicians.
Transparency remains the gatekeeper. CDS software that supports clinician decisions, rather than replacing them, has a clearer regulatory path. Tools must disclose logic, limitations, and intended use.
What remains restricted? Time-critical triage alerts, outputs prompting immediate medical management, and black-box recommendations. Glass Box is in, black box is out.
The same week as the FDA update, both major AI labs launched enterprise healthcare products.
OpenAI for Healthcare (January 8) includes ChatGPT for Healthcare, an enterprise workspace with GPT-5 models, HIPAA compliance, BAAs, and integration with Microsoft SharePoint. Early adopters include AdventHealth, Cedars-Sinai, HCA Healthcare, Stanford Medicine, and UCSF. The OpenAI API for Healthcare powers companies like Abridge and Ambience for ambient documentation and care coordination.
Claude for Healthcare (January 11) mirrors the approach: HIPAA-ready infrastructure, native connections to CMS Coverage Database, ICD-10, NPI Registry, and PubMed. Anthropic targets prior authorization, claims appeals, and care coordination workflows through a Microsoft Foundry partnership.
The pattern is clear. Both companies launched consumer features (ChatGPT Health, Claude health integrations), but the real investment is enterprise. Both emphasize evidence retrieval with citations, institutional policy alignment, and the principle that AI supports clinicians rather than replacing them.
What neither platform offers: specialized laboratory data processing. A chatbot that can discuss blood test results is not the same as infrastructure that normalizes LOINC codes across thousands of biomarker name variations, tracks longitudinal trends, and integrates with laboratory information systems at Quest Diagnostics, LabCorp, and regional health networks.
The January 2026 CDS guidance reinforces how we've been building from the start. BloodGPT was designed as a Glass Box before the term became regulatory shorthand.
Clinician-reviewable outputs. Every interpretation shows the basis for recommendations: guideline citations, patient-specific inputs, and what clinicians should verify. Whether interpreting alkaline phosphatase high results, ferritin levels, or cortisol patterns, the reasoning is transparent and clickable. Every recommendation traces back to its source.
Specialized laboratory intelligence. OpenAI and Anthropic can build chat interfaces. What they cannot replicate is FHIR-native integration, LOINC normalization across thousands of biomarker name variations, and longitudinal tracking that shows how AST blood test results relate to ALT levels and liver function trends over time. When patients search for "what is MCV in blood test" or clinicians need to interpret eGFR blood test results alongside creatinine patterns, generic AI falls short.
Enterprise integration. Healthcare organizations don't lack AI capabilities. They lack AI that handles their data formats, integrates with their laboratory information systems, and meets compliance requirements. Reference ranges vary between Quest Diagnostics, LabCorp, and regional facilities. We solve integration, not just intelligence.
Support, not replacement. The software is the tool; the clinician is the pilot. This is exactly the posture FDA describes for non-device CDS, and it's the liability framework that makes enterprise deployment possible.
Two weeks ago, healthcare AI was a compliance headache. Today, the FDA has clarified the path. OpenAI and Anthropic are deploying at major health systems. The early movers are already integrating.
Your competitors are reading the same headlines. Some are already scheduling demos. The question isn't whether laboratory AI becomes standard infrastructure. The question is whether you lead or follow.
The regulatory path for clinician-facing CDS has never been clearer. The market validation is complete. The technology is ready.
Start a pilot in 48 hours. We offer a sandbox environment for technical evaluation, API trial access for development teams, and white-label deployment for organizations ready to move. Lab Directors, CIOs, CMOs, and clinical leadership teams are already testing BloodGPT across clinical laboratories, health systems, and specialty practices.
Schedule a demo or reach out at [email protected].
About BloodGPT
BloodGPT provides AI-powered blood test interpretation and laboratory data analysis for healthcare organizations, clinical laboratories, and health systems. Our FHIR-native platform integrates with EHR systems, handles real-world lab data complexity through LOINC normalization, and delivers longitudinal intelligence that supports clinical decision-making. We offer white-label solutions, API integration, and on-premise deployment options for enterprise healthcare organizations. Learn more at bloodgpt.com.
References:
Transform how you deliver lab results to patients while enhancing your practice's efficiency and value. Try BloodGPT or contact us for a personalized demo
Book a Demo
